This week's update features Iovance Biotherapeutics' new cancer immunotherapy candidate IOV-4001 that was recently cleared for clinical trial...
At a Danish hospital, researchers have integrated CRISPR gene editing into a clinical scale workflow for immunotherapy. Gene editing releases a brake...
